

Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Programme

Distribution - 212204
Date Issued - 02 March 2022

Sample - 047
Closing Date - 22 March 2022

Participant ID -
Machine Used - FACSCanto II

Trial Comments

This exercise was issued to 87 participants. Please note: this report was generated after the issue of the initial trial report due to a request to the results submission deadline This is the final version of the report.

Sample Comments

The sample was manufactured by UK NEQAS using an AML patient sample, stabilised whole blood and CD34 rich stem cell harvest material. Please see additional commentary.

Results and Performance

Percentage MRD Population	Your Results (%)	Robust Mean (%)	Robust SD (%)
	0.3600	0.2000	0.1582

Percentage MRD Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
			12	0	0


***z Score Limits Definitions**

Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



Histograms of Participant z Scores

Percentage MRD Population - Please note ▼ denotes your result




Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Programme

Shewhart Control Charts

(Please note each data point represents a single sample)


Values (Percentage MRD Population)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Values (Percentage MRD Population)



Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Programme

Flow Cytometer Specific Statistics

(Please note only groups of >0 returns are displayed)



Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
DxFLEX	6	0.2442	0.1624
FACSCanto	2	0.1335	0.0938
FACSCanto II	25	0.2602	0.1860
FACSLyric	19	0.1049	0.0656
FACSVerse	1	0.4200	0.0000
LSR	1	0.1398	0.0000
LSR2	1	0.0000	0.0000
LSRFortessa	2	0.3405	0.0666
Navios	20	0.1299	0.0828

MRD Group Specific Statistics

(Please note only groups of >0 returns are displayed)



Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
iBFM	8	0.2516	0.2105
NOPHO	8	0.0933	0.0461
Not-Affiliated	48	0.2018	0.1671
Other	7	0.1905	0.1310
UK NCRI AML	1	0.0490	0.0000

Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Programme

Distribution - 212204

Sample - 048

Participant ID -

Date Issued - 02 March 2022

Closing Date - 22 March 2022

Machine Used - FACSCanto II

Trial Comments

This exercise was issued to 87 participants. Please note: this report was generated after the issue of the initial trial report due to a request to the results submission deadline This is the final version of the report.

Sample Comments

The sample was manufactured by UK NEQAS using an AML patient sample, stabilised whole blood and CD34 rich stem cell harvest material. Please see additional commentary.

Results and Performance

Percentage MRD Population	Your Results (%)	Robust Mean (%)	Robust SD (%)
	0.3190	0.1702	0.1592

Percentage MRD Population	z Score*	Performance Status for this Sample	Performance Status Classification Over 12 Sample Period		
			Satisfactory	Action	Critical
			12	0	0


***z Score Limits Definitions**

Please note the scale below is applicable to the tables above and to the z score histograms and Shewhart control charts that follow. It is not applicable to the Cusum control charts.



Histograms of Participant z Scores

Percentage MRD Population - Please note ▼ denotes your result




Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Programme

Shewhart Control Charts

(Please note each data point represents a single sample)


Values (Percentage MRD Population)



Cusum Control Charts

(Please note each data point represents the sum of the z scores of the current sample and the two previous samples)

Values (Percentage MRD Population)



Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Programme

Flow Cytometer Specific Statistics

(Please note only groups of >0 returns are displayed)

Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
DxFLEX	6	0.2201	0.1865
FACSCanto	2	0.1090	0.1074
FACSCanto II	25	0.2412	0.1443
FACSLyric	19	0.0648	0.0487
FACSVerse	1	0.3800	0.0000
LSR	1	0.1138	0.0000
LSR2	1	0.0000	0.0000
LSRFortessa	2	0.3215	0.0617
Navios	20	0.1011	0.0822

MRD Group Specific Statistics

(Please note only groups of >0 returns are displayed)

Method	Count Values (%)		
	Returns	Robust Mean	Robust SD
iBFM	7	0.2466	0.1855
NOPHO	8	0.0527	0.0328
Not-Affiliated	48	0.1775	0.1721
Other	7	0.1702	0.1523
UK NCRI AML	1	0.0230	0.0000